Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study - 19/08/20
Funding sources: This study was supported by Helsinn Therapeutics (US), Inc. Role of the funder: Design and conduct of the study; collection, management, analysis, and interpretation of data; and preparation, review, or approval of the manuscript. All authors made the decision to submit the manuscript for publication. |
|
Conflicts of interest: Dr Kim has received grant funding from Helsinn, Galderma, Kyowa Kirin, Medimmune, and Soligenix; consulted for Helsinn and the PROVe Scientific Committee, Galderma, and WebMD; and served on an advisory board for Seattle Genetics. Dr Geskin has received grant funding and has consulted for Helsinn. Dr Guitart has received grant funding and had consulted for Helsinn, received grant funding from Galderma, Medivir, and Soligenix, and has consulted for Miragen and LEO Pharma. Dr Querfeld has consulted for Miragen, Helsinn, Mallinckrodt, Medivir, and Kyowa Kirin and received grant funding from STOP Cancer, the Leukemia & Lymphoma Society, Trillium, and Celgene Corp. Dr Girardi has consulted for Helsinn, Mallinckrodt, Transimmune, and Sanofi and received grant funding from Helsinn, Soligenix, and AbbVie. Dr Musiek has received grant funding and consulted for Helsinn, Elorac, Kyowa Kirin, Soligenix, and Pfizer; served on advisory board for Helsinn, Kyowa Kirin, and Seattle Genetics, and served on a speakers bureau for Helsinn. Mr Mink and Dr Williams are employed by ICON Commercialization & Outcomes. Dr Angello and Dr Bailey are employed by Helsinn Therapeutics (US), Inc. |
|
IRB approval status: Reviewed and approved where applicable. |
Vol 83 - N° 3
P. 928-930 - septembre 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?